Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
@jackson
Speak with FACT not lies
This is a fact. just watch these video they explain everything you need to know about past, present and future plus everything else.
*********************************
Watch the MGC Pharma #MXC? webinar hosted by Vox Markets & Turner Pope Investments
https://youtu.be/qikchrfhkho
************************************
MGC Pharma's new head of global sales has big ambitions and says they're 'ready to go'
https://youtu.be/atRbVcHOyeY
***********************************
MGC Pharma – Edison Open House interview
https://youtu.be/itKwpRlACB0
***********************************
MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19
https://youtu.be/04dKV8oDIqU
Before you going out, watch these videos. This are the Fact. The price going down no because is something is wrong with the company its because the whole market is down. In this videos you can find out about the company past, present and future
*********************************
Watch the MGC Pharma #MXC? webinar hosted by Vox Markets & Turner Pope Investments
https://youtu.be/qikchrfhkho
************************************
MGC Pharma's new head of global sales has big ambitions and says they're 'ready to go'
https://youtu.be/atRbVcHOyeY
***********************************
MGC Pharma – Edison Open House interview
https://youtu.be/itKwpRlACB0
***********************************
MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19
https://youtu.be/04dKV8oDIqU
Tanks Ironaz
I can see someone in a green box here. I don't know what you are saying, fortunately.
but speak with FACTS
If your new MXC investors watch this
*********************************
Watch the MGC Pharma #MXC? webinar hosted by Vox Markets & Turner Pope Investments
https://youtu.be/qikchrfhkho
************************************
MGC Pharma's new head of global sales has big ambitions and says they're 'ready to go'
https://youtu.be/atRbVcHOyeY
***********************************
MGC Pharma – Edison Open House interview
https://youtu.be/itKwpRlACB0
***********************************
MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19
https://youtu.be/04dKV8oDIqU
FACTS
1. CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy
* Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes
2.CogniCann® is MGC Pharma’s second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer’s disease patients quality of life
*Available to prescribe in Australia as an Investigational Medicinal Product through Early Patient Access Scheme
MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via
an extensive network of commercial partners meaning that it is poised to supply the global market.
These products are the outcome of years of experience and development of our medical team, produced under strict GMP guidelines with QA/QC/QP controls and audit
Slovenian EU-GMP certified facility has the capacity to manufacture up to 12,000 prescription products per month – 3 years GMP license granted.
Based on 5,000 units per month, the Company would be at operating cash flow breakeven, excluding Research costs.
Extensive network in place providing access to hospitals, pharmacies, and research institutions around the world – Lenis is
the Company’s wholesaler/exporter to all distributors globally and is also a direct distributor to key European markets. The
Acquisition of Medicinal Cannabis Clinics also provides distribution and direct patient access across Australia
QUALIFIED MANUFACTURING
• EU-GMP certification granted at Slovenian facility for production of phytocannabinoid based Investigational Medicinal Products (Europe)
• Production capabilities at the Malta facility,
once operational, is to support over 5,000 patient per month at full capacity1
• SME approval by the European Medicines Agency (EMA) for scientific advice and incentives
this is a FACT.
that's a problem with these people and deramper they don't talk with FACT.
Thanks, Bushmaster
Bushmaster, You didn't miss anything mate.
If you read this BB today it will make you sick.
This is a fact. just watch these videos you will get all your answer. don't look at numbers
*********************************
Watch the MGC Pharma #MXC? webinar hosted by Vox Markets & Turner Pope Investments
https://youtu.be/qikchrfhkho
************************************
MGC Pharma's new head of global sales has big ambitions and says they're 'ready to go'
https://youtu.be/atRbVcHOyeY
***********************************
MGC Pharma – Edison Open House interview
https://youtu.be/itKwpRlACB0
***********************************
MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19
https://youtu.be/04dKV8oDIqU
This is a fact. just watch these videos
*********************************
Watch the MGC Pharma #MXC? webinar hosted by Vox Markets & Turner Pope Investments
https://youtu.be/qikchrfhkho
************************************
MGC Pharma's new head of global sales has big ambitions and says they're 'ready to go'
https://youtu.be/atRbVcHOyeY
***********************************
MGC Pharma – Edison Open House interview
https://youtu.be/itKwpRlACB0
***********************************
MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19
https://youtu.be/04dKV8oDIqU
Good find mate. Thanks
you absolutely right, and I tell you one more thing.
If in a few month's time they don't pass phase 3 for ArtemiCTM this share price would go down to 1p. I know that and other people need to know that too.
So based on that my money my own risk and you guys decide for yourself too. your money your own risk
Ok listen, guys,
a few years ago when I was new to investing, I bought a few thousand shares in NIO and ITM at that time. ( ITM / 0.75p and NIO / $1.50 per share ).
I didn't know what does research means at that time I just bought in base on what people saying on the BB and sold it again base on what people were saying on the BB. I was mange to get read off dose shares whit little money out.
from my past experience, I learned in a hard way what does means to do your own research. I still can't forgive myself for selling my shares at that time.
however, for MGC I did my research one week befor they coming to the UK market. whatever these people saying on this BB
I knew about it before I put my money here nothing new.
just listen to these people here about MGC, you ask them why you think MGC is a bad company to invest in they talk about what was happened to the company in 2012 our the other guy tells you to go to read the Australian BB.
SHOCKING
Always talk with FACT.
I'm sorry to say this but I don't give the F@@K to this b@ll****. I buy base on my own research and sell base on my own research.
My money my own risk and same for you too your money your own risk.
BUY, SELL, HOLD OR TOPUP just do it base on your own research, not BB research.
Have a nice day
Sorry guys I need to share this here one more time for new investors
2020 highlights
1. The 2021 half-year represented a strategically important period for the Group and thus far MGC Pharma has delivered significant progress on an upward growth trajectory as it delivers on its growth strategy.
2. The Group delivered total sales for the half-year of $741,911 in pharma revenue (2019: $134,536).
3. First shipment of MP Line products directly to patients in Brazil. MGC Pharma is the first company globally to ship high THC formulations directly to a patient's door in Brazil
4. $5 million cash grant to establish ArtemiCTM production in Malta. Construction of new facility commenced during the December quarter and will be completed in mid-2021
5. Launch of CannEpil® App
6. Completion of Phase II clinical trial on COVID-19 patients.
The trial met all the FDA requirements for a COVID-19 study including population diversity (age, medical history, and genetic diversity), and demonstrated a full safety profile with no drug-related adverse events.
7. Further successful results from pre-clinical glioblastoma research.
Results from the ongoing pre-clinical research program focused on evaluating cannabinoid formulations in the development of a treatment of the most aggressive and therapeutically resistant brain tumour, glioblastoma, have shown further successful results.
If successful, this would potentially lead to a significant breakthrough in the treatment of brain cancer through oral administration (rather than invasive treatments).
8. Binding term sheet signed for the import and sales of CannEpil® in Israel.
MGC Pharma executed a binding term sheet with IM Cannabis Corp. (IMC), one of the leading cannabis companies in Israel with operations in Europe, for the exclusive wholesale import, sales, and distribution of CannEpil® in Israel.
In Europe, IMC has established a medical cannabis operation first with its distribution subsidiary in Germany and augmented by strategic agreements with EU-GMP standard certified suppliers.
9. $15M Finance Facility
In September 2020, a convertible securities financing agreement was signed with Mercer Street Global Opportunity Fund, LLC ("Mercer"), to provide the Group with funding of up to a total of $15 million.
10. Following the London Stock Exchange listing and associated share placement, the Group is in a strong financial position to pursue identified growth initiatives.
11. With the successful results of phase II clinical trials on ArtemiCTM, a phase III trial is planned to commence in the June quarter.
The problem with OZ is people bought the share in MGC in 2012. without any research.
they have bought in when the company didn't have any medicine in the market, top-up that needs to burn lots of cash to do the research, and no contract or revenue.
and again they doing the same mistake to sell in 2021 without any research. when the company have 3 medicine in the market and have a contract plus good revenue for next three years and lots more to come up.
good examples Irontaz. look at the MGC now, they have products, contracts, and revenue.
because it wasn't any products to sell since 2012. that was to early for investors to buy a share for this company.
if you look closely you can see in the beginning, the company was trying to do the research and had a big cash burn to get the products ready for the market.
I can say they actually start to move from 2019. but I think from this year 2021 the journey begins for the company.
so the company didn't need to move to the bigger market in 2012 because it was pointless if they were moved to the UK in 2012 with nothing in hand.
Some good info here about GWP shareholders when it was delist in the UK AIM market.
https://www.google.com/url?sa=t&source=web&rct=j&url=https://ir.gwpharm.com/static-files/584a19c5-c3c8-40a0-83a2-067ae85cb8e4&ved=2ahUKEwjfvJHNsZTvAhU8UBUIHeq_CvoQFjAAegQIAxAD&usg=AOvVaw3PUhuF2oISjIKhm0K9oT_G
I know they moved frome AIM market straight to NASDAQ when the shares price rich to around £3. So what happened to shareholders I don't know.
But MGC is on main market here so if they list the company on NASDAQ it would be same for us.
I think it was 30p on AIM market.